Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III Sells 55,453 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 55,453 shares of Pulmonx stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the sale, the director now directly owns 1,011,974 shares in the company, valued at $8,379,144.72. This represents a 5.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Pulmonx Trading Down 0.4 %

Pulmonx stock opened at $8.92 on Tuesday. The stock has a 50-day simple moving average of $6.59 and a 200 day simple moving average of $6.81. The stock has a market capitalization of $352.25 million, a P/E ratio of -6.19 and a beta of 0.64. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a 52 week low of $5.46 and a 52 week high of $11.10.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. Analysts expect that Pulmonx Co. will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Stifel Nicolaus decreased their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Citigroup restated a “neutral” rating and issued a $7.50 price target (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company dropped their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Hedge Funds Weigh In On Pulmonx

Several institutional investors and hedge funds have recently modified their holdings of the stock. 272 Capital LP acquired a new stake in shares of Pulmonx during the 3rd quarter worth about $25,000. BNP Paribas Financial Markets bought a new position in Pulmonx in the 4th quarter valued at about $43,000. R Squared Ltd acquired a new stake in Pulmonx during the fourth quarter worth approximately $46,000. ProShare Advisors LLC bought a new stake in shares of Pulmonx during the fourth quarter worth approximately $72,000. Finally, Stifel Financial Corp acquired a new position in shares of Pulmonx in the fourth quarter valued at approximately $81,000. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.